Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2021

View Archived Issues

Engineered cartilage secretes anti-inflammatory drug

Evotec initiates clinical development of chikungunya antibody EVT-894

FDA clears IND application for SQZ AACs in patients with HPV-positive tumors

Promising phase I data presented for tau monoclonal antibody PNT-001

Virios announces collaboration to evaluate its IMC-1 antiviral in patients with IBS

Topline data from pivotal DERMIS-1 and -2 studies of ARQ-151 in plaque psoriasis

Phase II study of CTP-692 in schizophrenia does not meet primary or secondary endpoints

Noveome and WRAIR collaborate to develop ST-266 for traumatic brain injury

Sun Pharma Advanced Research describes new camptothecin derivative prodrugs

New anti-influenza compounds identified at Nanjing Zhengxiang Pharmaceuticals

New LRRK2 inhibitors discovered at E-Scape Bio

Pharmaleads patents neprilysin and aminopeptidase N inhibitors

Mobocertinib shows clinical benefit in patients with exon 20-mutated NSCLC

Compounds for treating hepatitis B infection identified at Enanta Pharmaceuticals

Interim phase I data for SCB-2019 reveal robust immune responses against SARS-CoV-2

T-DXd shows preliminary evidence of antitumor activity in metastatic HER2-overexpressing NSCLC

Ampio expands phase I trial of Ampion for COVID-19 respiratory distress based on early data

Prothena plans phase III study of birtamimab for patients with Mayo stage IV AL amyloidosis

CD40-targeting vaccine enhances T- and B-cell responses against HIV-1

Tiziana reports data from exploratory trial of nasally administered foralumab for COVID-19

Updated results presented from TRIDENT-1 study of repotrectinib

WCLC 2021: KRAS drugs may do best in tough subtype

Phase II trial of ensifentrine pMDI formulation in COPD meets lung function endpoints

Phase III study of sparsentan in FSGS achieves interim proteinuria endpoint

Immunovant pauses dosing in trials of IMVT-1401

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...